FREEHOLD, N.J.—Further expanding commercialization of European products, New Life Scientific (NWLS) announced a strategic alliance with Biorigen Srl, a biotech company, and Centro Biotecnologie Avanzate, both based in Genoa, Italy, to push tissue engineering for bone repair. Under the agreement, NWLS will retain global rights, with the exception of the European Union and countries of the Mediterranean Basin and Middle East, to any products arising from the joint venture.

 

The bone reconstruction project will be based on technology that expands mesechymal stem cells in culture for more efficient and reproduceable healing. Biorigen will be responsible for preclinical product development, but will then work with NWLS to push the product through the clinical process. NWLS will then take over the registration and marketing in assigned market territories.